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Avoiding Antiplatelet Reversal in Non-Operative Intracranial Hemorrhages: Functional
Outcomes of Guideline-Based Practice
Angelo d’Antonio-Bertagnolli BS, Lyena Birkenstock BS, Ariva Mobaraki BS, Christine
Hammer MD, Syed O Shah MD, Jack Jallo MD PhD, Courtney Pendleton MD*
(*) indicates primary project advisor
(**) indicates another student who is declaring the same project as primary for SI
Introduction: Intracranial hemorrhage (ICH) is a common, life-threatening neurological
pathology in aging patients, many of whom take antiplatelet medications with potential to
worsen the hemorrhage. In the event of ICH, Thomas Jefferson University Hospital (TJUH)
follows a protocol modeling the 2016 Neurocritical Care Society (NCS) joint guidelines for
antiplatelet medication reversal. We analyzed pre- and post-NCS guideline data from TJUH for
outcomes of non-operative ICH patients in order to tease out the potential benefits of this
protocol.
Methods: This retrospective cohort study took place from January 2016 – Jan. 2018 at a tertiary
care center: TJUH. Patients included were 18 y.o., on antiplatelet therapy who, had CTs
available for evaluation of expansion, and did not undergo surgical management. The primary
outcomes measured for comparison were both the admission and discharge Glasgow Coma
Scores (GCS), admission and discharge modified Rankin Scores (mRS), time to death,
hematoma expansion, and in-hospital mortality. T-tests, the Kolmogorov-Smirnov-test, and ChiSquare test for independence were used.

Results: For pre- and post-protocol groups, no significant difference existed for GCS or mRS, at
admission and discharge. There were no significant findings for in-hospital mortality and
hemorrhage expansion.
Discussion: TJUH established a protocol in line with the 2016 NCS joint guidelines for
managing ICH in patients on antiplatelet therapies. This protocol recommends discontinuing
antiplatelet therapy and not transfusing platelets in patients not receiving surgical management.
We examined the protocol efficacy have found no significant differences in the pre- and postprotocol groups, indicating patient outcomes may be equivalent.

